Galcanezumab in chronic migraine: The randomized, double-blind, placebo-controlled REGAIN study

Lignende værker

• Changes in patient functioning and disability: results from a phase 3, double-blind, randomized, placebo-controlled clinical trial evaluating galcanezumab for chronic migraine prevention (REGAIN)
  af: Ford, Janet, et al.
  Udgivet: (2020)
• Analysis of Initial Nonresponders to Galcanezumab in Patients With Episodic or Chronic Migraine: Results From the EVOLVE‐1, EVOLVE‐2, and REGAIN Randomized, Double‐Blind, Placebo‐Controlled Studies
  af: Nichols, Russell, et al.
  Udgivet: (2018)
• Preventive effects of galcanezumab in adult patients with episodic or chronic migraine are persistent: data from the phase 3, randomized, double-blind, placebo-controlled EVOLVE-1, EVOLVE-2, and REGAIN studies
  af: Förderreuther, Stefanie, et al.
  Udgivet: (2018)
• Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine
  af: Goadsby, Peter J, et al.
  Udgivet: (2019)
• Phase 3 randomized, placebo-controlled study of galcanezumab in patients with chronic cluster headache: Results from 3-month double-blind treatment
  af: Dodick, David W, et al.
  Udgivet: (2020)